Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
MoonLake Immunotherapeutics - Class A Ordinary Shares
(NQ:
MLTX
)
46.81
-0.11 (-0.23%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MoonLake Immunotherapeutics - Class A Ordinary Shares
< Previous
1
2
3
4
5
Next >
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
June 10, 2024
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
May 16, 2024
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MLTX Stock Earnings: MoonLake Misses EPS for Q1 2024
May 07, 2024
MLTX stock results show that MoonLake missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
April 10, 2024
From
Komodo Health
Via
Business Wire
Expert Ratings for MoonLake
November 27, 2023
Via
Benzinga
Recap: MoonLake Q3 Earnings
November 14, 2023
Via
Benzinga
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 10, 2024
Via
Benzinga
MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
March 11, 2024
The company tested its psoriatic arthritis drug over 24 weeks against Humira.
Via
Investor's Business Daily
16 Analysts Have This to Say About MoonLake
November 07, 2023
Via
Benzinga
Where MoonLake Stands With Analysts
October 16, 2023
Via
Benzinga
Why Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today?
March 11, 2024
Results with MoonLake Immunotherapeutics' Nanobody sonelokimab in Psoriatic Arthritis. Achieve over 60% ACR50, 40% ACR70, and 80% PASI90 by week 24. Unprecedented improvements compared to competitors.
Via
Benzinga
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
March 10, 2024
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
March 04, 2024
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
March 01, 2024
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
February 26, 2024
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 20, 2023
Via
Benzinga
Why Former Highflier MoonLake Plummeted 29% After A Recent Run
November 06, 2023
The company tested its drug over 12 weeks in 207 patients. All but one regimen led to statistically significant improvements.
Via
Investor's Business Daily
Dow Turns Lower; EchoStar Shares Plunge
November 06, 2023
U.S. stocks turned lower toward the end of trading, with the Dow Jones falling around 50 points on Monday The Dow traded down 0.16% to 34,007.81 while the NASDAQ fell 0.08% to 13,467.42. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session
November 06, 2023
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
November 06, 2023
Via
Benzinga
Crude Oil Moves Higher; BioNTech Lowers 2023 Sales Outlook
November 06, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 40 points on Monday The Dow traded up 0.13% to 34,106.99 while the NASDAQ rose 0.16% to 13,499.42. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Is Arthritis-Focused MoonLake Immunotherapeutics Stock Trading Lower Today?
November 06, 2023
Sunday, MoonLake Immunotherapeutics (NASDAQ: MLTX) released topline results from its global Phase 2 ARGO trial of Nanobody sonelokimab in patients with
Via
Benzinga
TreeHouse Foods, EchoStar, Hilton Grand Vacations, EchoStar And Other Big Stocks Moving Lower On Monday
November 06, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 25 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
US Stocks Rise; Nasdaq Gains 50 Points
November 06, 2023
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday Following the market opening Monday, the Dow traded up 0.21% to 34,133.62 while the NASDAQ rose...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 06, 2023
Via
Benzinga
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
November 05, 2023
From
MoonLake Immunotherapeutics AG
Via
GlobeNewswire
MoonLake Immunotherapeutics' Lead Skin Disorder Candidate Continues to Deliver on Best-Efficacy Profile: Analyst
October 16, 2023
MoonLake Immunotherapeutics (NASDAQ: MLTX) announced 24-week topline results from its Phase 2 MIRA trial of sonelokimab for moderate-to-severe hidradenitis suppurativa (HS), following the 12-week...
Via
Benzinga
Lululemon, PCTEL, Consolidated Communications, Other Stocks Jumping Higher On Monday
October 16, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Monday. Here are some stocks recording big gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session
October 16, 2023
Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday.
Via
Benzinga
Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout
October 16, 2023
MoonLake says it's skin-disease treatment showed improved promise in a 24-week testing update.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.